Managed Care

COPD inhalers – hold your breath

Krishna Rutvij Patel, PharmD

With the approval of Breo Ellipta in May 2013 and Anoro Ellipta in December 2013, formulary decision makers are faced with more treatment options for chronic obstructive pulmonary disease (COPD) than ever before. There are now three inhalers that are combination products of a long-acting beta agonist and a glucocorticoid that can potentially help patients with moderate to severe COPD. Research comparing these available therapeutic options is limited, making differentiation difficult. Despite that, let’s take a look at several notable differences among these drugs.

Administration once daily Administration twice daily Black box warning Approved for COPD Approved for asthma Recommended in GOLD guidelines for moderate–severe COPD
Advair
Breo Ellipta
Symbicort
Source: GOLD (Global Initiative for Chronic Obstructive Lung Disease)

Subscribe to Our Newsletters

Monthly table of contents

Be notified as each issue of Managed Care is available online.

Biweekly newsletter

Recent topics have included:

  • Doug Jones and the ACA, Epic misses a White House meeting, and man caves for man-flu sufferers
  • CVS-Aetna deal may trigger merger mania, Johns Hopkins criticized for lack of asthma prevention, & Columbia sees free-ride future for all of its med students

PTCommunity news

New drug approvals, clinical trials, drug management. Three times per week.